| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 35 | 2022 | 505 | 9.410 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 15 | 2021 | 216 | 5.630 |
Why?
|
| Pneumonectomy | 20 | 2022 | 67 | 5.430 |
Why?
|
| Thoracic Surgery | 14 | 2022 | 23 | 5.030 |
Why?
|
| Esophageal Neoplasms | 8 | 2022 | 43 | 3.830 |
Why?
|
| Databases, Factual | 13 | 2021 | 325 | 2.360 |
Why?
|
| Adenocarcinoma | 8 | 2018 | 123 | 2.150 |
Why?
|
| Societies, Medical | 11 | 2020 | 146 | 2.130 |
Why?
|
| Thoracic Surgical Procedures | 5 | 2019 | 8 | 1.830 |
Why?
|
| Neoplasm Staging | 13 | 2021 | 313 | 1.790 |
Why?
|
| Humans | 74 | 2023 | 26028 | 1.590 |
Why?
|
| Postoperative Complications | 8 | 2022 | 862 | 1.450 |
Why?
|
| Thoracic Wall | 3 | 2016 | 10 | 1.430 |
Why?
|
| Quality Improvement | 4 | 2019 | 150 | 1.350 |
Why?
|
| Thoracic Surgery, Video-Assisted | 7 | 2021 | 18 | 1.170 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 185 | 1.140 |
Why?
|
| Biomarkers, Tumor | 7 | 2022 | 179 | 1.130 |
Why?
|
| Aged | 33 | 2021 | 8705 | 1.080 |
Why?
|
| Lung | 5 | 2022 | 155 | 1.070 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2015 | 35 | 1.000 |
Why?
|
| Female | 39 | 2022 | 14399 | 0.970 |
Why?
|
| Male | 41 | 2022 | 14011 | 0.940 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2016 | 32 | 0.890 |
Why?
|
| Laparoscopy | 3 | 2022 | 159 | 0.870 |
Why?
|
| Colonic Neoplasms | 3 | 2017 | 50 | 0.850 |
Why?
|
| Robotics | 2 | 2013 | 16 | 0.830 |
Why?
|
| Biology | 1 | 2022 | 7 | 0.830 |
Why?
|
| Phosphoproteins | 1 | 2022 | 25 | 0.820 |
Why?
|
| Middle Aged | 28 | 2022 | 8509 | 0.810 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2022 | 3 | 0.800 |
Why?
|
| Registries | 2 | 2021 | 171 | 0.770 |
Why?
|
| Retrospective Studies | 18 | 2022 | 3299 | 0.770 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 26 | 0.750 |
Why?
|
| Advisory Committees | 2 | 2018 | 22 | 0.730 |
Why?
|
| Surgical Oncology | 1 | 2020 | 4 | 0.730 |
Why?
|
| Checklist | 1 | 2020 | 36 | 0.700 |
Why?
|
| Prognosis | 9 | 2022 | 750 | 0.700 |
Why?
|
| Lymphadenopathy | 1 | 2020 | 1 | 0.700 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 277 | 0.680 |
Why?
|
| Gases | 1 | 2019 | 5 | 0.670 |
Why?
|
| Intubation, Gastrointestinal | 2 | 2010 | 10 | 0.660 |
Why?
|
| Hate | 1 | 2019 | 2 | 0.660 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2019 | 160 | 0.660 |
Why?
|
| Chest Tubes | 1 | 2019 | 3 | 0.660 |
Why?
|
| Thoracotomy | 3 | 2021 | 21 | 0.660 |
Why?
|
| Inhibin-beta Subunits | 2 | 2009 | 2 | 0.650 |
Why?
|
| Clostridium Infections | 2 | 2009 | 20 | 0.640 |
Why?
|
| Catheter Ablation | 1 | 2020 | 65 | 0.640 |
Why?
|
| Enteral Nutrition | 2 | 2010 | 58 | 0.640 |
Why?
|
| Aged, 80 and over | 15 | 2018 | 4660 | 0.630 |
Why?
|
| Diaphragm | 1 | 2018 | 8 | 0.610 |
Why?
|
| Heart Diseases | 2 | 2016 | 56 | 0.610 |
Why?
|
| Mucous Membrane | 1 | 2018 | 28 | 0.600 |
Why?
|
| Foreign-Body Migration | 1 | 2018 | 19 | 0.600 |
Why?
|
| Scoliosis | 1 | 2018 | 32 | 0.580 |
Why?
|
| Adult | 16 | 2018 | 7364 | 0.580 |
Why?
|
| Risk Assessment | 5 | 2019 | 622 | 0.580 |
Why?
|
| Prosthesis Failure | 2 | 2018 | 506 | 0.580 |
Why?
|
| Internationality | 1 | 2017 | 24 | 0.570 |
Why?
|
| Databases as Topic | 1 | 2017 | 14 | 0.570 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 38 | 0.560 |
Why?
|
| Benchmarking | 1 | 2017 | 35 | 0.560 |
Why?
|
| Cardiology | 1 | 2016 | 43 | 0.530 |
Why?
|
| Ribs | 1 | 2016 | 13 | 0.530 |
Why?
|
| Metformin | 1 | 2016 | 18 | 0.520 |
Why?
|
| United States | 9 | 2021 | 1981 | 0.520 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 33 | 0.520 |
Why?
|
| Nurse Practitioners | 1 | 2017 | 102 | 0.520 |
Why?
|
| Pulmonary Blastoma | 1 | 2015 | 4 | 0.510 |
Why?
|
| Mediastinal Neoplasms | 1 | 2015 | 11 | 0.510 |
Why?
|
| Neoplasm Invasiveness | 4 | 2018 | 77 | 0.510 |
Why?
|
| Testicular Neoplasms | 1 | 2015 | 18 | 0.510 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 126 | 0.510 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2015 | 13 | 0.500 |
Why?
|
| Lung Diseases, Fungal | 1 | 2015 | 10 | 0.490 |
Why?
|
| Mucormycosis | 1 | 2015 | 9 | 0.490 |
Why?
|
| Early Medical Intervention | 1 | 2015 | 15 | 0.490 |
Why?
|
| Treatment Outcome | 13 | 2021 | 3293 | 0.490 |
Why?
|
| Quality of Health Care | 1 | 2016 | 121 | 0.470 |
Why?
|
| Survival Rate | 7 | 2021 | 321 | 0.470 |
Why?
|
| Surgical Mesh | 1 | 2014 | 22 | 0.460 |
Why?
|
| Risk Adjustment | 3 | 2020 | 10 | 0.460 |
Why?
|
| Herniorrhaphy | 1 | 2014 | 30 | 0.460 |
Why?
|
| Manubrium | 1 | 2014 | 2 | 0.460 |
Why?
|
| Replantation | 1 | 2014 | 8 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 224 | 0.450 |
Why?
|
| Clavicle | 1 | 2014 | 14 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 291 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 173 | 0.440 |
Why?
|
| Esophagectomy | 3 | 2022 | 20 | 0.420 |
Why?
|
| Tricuspid Valve Prolapse | 1 | 2012 | 1 | 0.420 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2012 | 1 | 0.420 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 353 | 0.410 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2012 | 20 | 0.410 |
Why?
|
| Prostheses and Implants | 1 | 2014 | 159 | 0.410 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 53 | 0.400 |
Why?
|
| Cell Line, Tumor | 4 | 2022 | 230 | 0.380 |
Why?
|
| Survival Analysis | 3 | 2018 | 235 | 0.370 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2018 | 713 | 0.370 |
Why?
|
| Spinal Fusion | 1 | 2018 | 473 | 0.360 |
Why?
|
| Simulation Training | 2 | 2021 | 38 | 0.360 |
Why?
|
| Myxoma | 1 | 2010 | 4 | 0.350 |
Why?
|
| Heart Neoplasms | 1 | 2010 | 8 | 0.350 |
Why?
|
| Mitral Valve | 1 | 2010 | 9 | 0.350 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 63 | 0.350 |
Why?
|
| Energy Intake | 1 | 2010 | 71 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 95 | 0.330 |
Why?
|
| Aneurysm, Infected | 1 | 2009 | 1 | 0.330 |
Why?
|
| Clostridium septicum | 1 | 2009 | 1 | 0.330 |
Why?
|
| Aortitis | 1 | 2009 | 2 | 0.330 |
Why?
|
| Embolism | 1 | 2009 | 2 | 0.330 |
Why?
|
| Embolectomy | 1 | 2009 | 3 | 0.330 |
Why?
|
| Blood Component Transfusion | 1 | 2009 | 3 | 0.330 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2009 | 4 | 0.330 |
Why?
|
| Jehovah's Witnesses | 1 | 2009 | 3 | 0.330 |
Why?
|
| Treatment Refusal | 1 | 2009 | 11 | 0.330 |
Why?
|
| Length of Stay | 4 | 2016 | 302 | 0.330 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2018 | 17 | 0.330 |
Why?
|
| Aortic Aneurysm | 1 | 2009 | 12 | 0.330 |
Why?
|
| Ischemia | 1 | 2009 | 20 | 0.320 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2009 | 11 | 0.320 |
Why?
|
| Religion and Medicine | 1 | 2009 | 22 | 0.320 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 63 | 0.320 |
Why?
|
| Bronchoscopy | 3 | 2019 | 28 | 0.320 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 68 | 0.310 |
Why?
|
| Internship and Residency | 3 | 2018 | 206 | 0.310 |
Why?
|
| Risk Factors | 4 | 2022 | 2244 | 0.310 |
Why?
|
| Surgeons | 2 | 2020 | 76 | 0.310 |
Why?
|
| Hospital Costs | 1 | 2008 | 63 | 0.300 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 74 | 0.300 |
Why?
|
| Critical Care | 1 | 2010 | 190 | 0.290 |
Why?
|
| Sarcoma | 2 | 2021 | 142 | 0.280 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 1712 | 0.270 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 158 | 0.270 |
Why?
|
| Trachea | 2 | 2022 | 45 | 0.270 |
Why?
|
| Intensive Care Units | 1 | 2008 | 279 | 0.270 |
Why?
|
| Clinical Competence | 3 | 2020 | 211 | 0.260 |
Why?
|
| Early Detection of Cancer | 4 | 2022 | 85 | 0.250 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 33 | 0.240 |
Why?
|
| Biomarkers | 2 | 2017 | 549 | 0.240 |
Why?
|
| Surgical Flaps | 2 | 2015 | 50 | 0.230 |
Why?
|
| Chemoradiotherapy | 2 | 2015 | 61 | 0.220 |
Why?
|
| Embolism, Air | 1 | 2023 | 8 | 0.220 |
Why?
|
| Consensus | 2 | 2021 | 83 | 0.220 |
Why?
|
| Bronchi | 2 | 2015 | 11 | 0.210 |
Why?
|
| Thymoma | 2 | 2020 | 7 | 0.210 |
Why?
|
| Thymus Neoplasms | 2 | 2020 | 9 | 0.210 |
Why?
|
| Thrombosis | 1 | 2023 | 51 | 0.210 |
Why?
|
| Blood Coagulation Disorders | 1 | 2022 | 14 | 0.210 |
Why?
|
| Hemostatics | 1 | 2022 | 10 | 0.210 |
Why?
|
| Computer Simulation | 2 | 2021 | 193 | 0.210 |
Why?
|
| Carbon Monoxide | 1 | 2022 | 7 | 0.210 |
Why?
|
| Intubation, Intratracheal | 2 | 2016 | 93 | 0.200 |
Why?
|
| Lymph Nodes | 2 | 2020 | 62 | 0.200 |
Why?
|
| Cohort Studies | 4 | 2018 | 1823 | 0.200 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 14 | 0.200 |
Why?
|
| Metastasectomy | 1 | 2021 | 7 | 0.200 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 295 | 0.190 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2021 | 10 | 0.190 |
Why?
|
| Patient Discharge | 1 | 2022 | 146 | 0.190 |
Why?
|
| Incidence | 2 | 2021 | 713 | 0.180 |
Why?
|
| Heart-Assist Devices | 1 | 2021 | 15 | 0.180 |
Why?
|
| Mass Screening | 2 | 2022 | 166 | 0.180 |
Why?
|
| Mediastinal Cyst | 1 | 2020 | 1 | 0.170 |
Why?
|
| RNA, Messenger | 3 | 2009 | 264 | 0.170 |
Why?
|
| Carcinoma | 2 | 2017 | 59 | 0.170 |
Why?
|
| Smoking | 1 | 2020 | 169 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 7 | 0.160 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 64 | 0.160 |
Why?
|
| False Positive Reactions | 1 | 2019 | 32 | 0.160 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2022 | 52 | 0.160 |
Why?
|
| Drainage | 1 | 2019 | 46 | 0.160 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 68 | 0.160 |
Why?
|
| Sensitivity and Specificity | 4 | 2018 | 485 | 0.160 |
Why?
|
| Heart Failure | 1 | 2021 | 167 | 0.160 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 26 | 0.160 |
Why?
|
| Obesity | 1 | 2021 | 277 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2009 | 161 | 0.160 |
Why?
|
| Thoracoscopy | 3 | 2019 | 20 | 0.160 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2018 | 7 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 305 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2009 | 161 | 0.150 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 6 | 0.150 |
Why?
|
| HLA Antigens | 1 | 2018 | 15 | 0.150 |
Why?
|
| Hemoptysis | 1 | 2018 | 7 | 0.150 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 22 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 335 | 0.150 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2018 | 11 | 0.150 |
Why?
|
| Syndecan-1 | 1 | 2018 | 4 | 0.150 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2018 | 17 | 0.150 |
Why?
|
| Chest Pain | 1 | 2018 | 19 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 342 | 0.150 |
Why?
|
| Morbidity | 2 | 2019 | 55 | 0.150 |
Why?
|
| Immunoassay | 1 | 2018 | 37 | 0.150 |
Why?
|
| Nerve Growth Factors | 1 | 2018 | 35 | 0.150 |
Why?
|
| Tracheomalacia | 1 | 2017 | 2 | 0.140 |
Why?
|
| Tracheal Stenosis | 1 | 2017 | 4 | 0.140 |
Why?
|
| Silicones | 1 | 2017 | 9 | 0.140 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 5 | 0.140 |
Why?
|
| Airway Obstruction | 1 | 2017 | 17 | 0.140 |
Why?
|
| Suture Techniques | 1 | 2018 | 147 | 0.140 |
Why?
|
| Lymphoma | 1 | 2017 | 36 | 0.140 |
Why?
|
| Stents | 1 | 2017 | 73 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2016 | 23 | 0.140 |
Why?
|
| Melanoma | 1 | 2017 | 48 | 0.140 |
Why?
|
| History, 19th Century | 1 | 2016 | 29 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2016 | 45 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 30 | 0.140 |
Why?
|
| Biopsy | 1 | 2017 | 199 | 0.140 |
Why?
|
| Adolescent | 1 | 2022 | 2064 | 0.140 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 8 | 0.130 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2016 | 7 | 0.130 |
Why?
|
| Tracheostomy | 1 | 2016 | 23 | 0.130 |
Why?
|
| Europe | 1 | 2016 | 65 | 0.130 |
Why?
|
| Prospective Studies | 1 | 2021 | 1659 | 0.130 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2010 | 308 | 0.130 |
Why?
|
| Etoposide | 1 | 2015 | 25 | 0.130 |
Why?
|
| Ifosfamide | 1 | 2015 | 13 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2016 | 122 | 0.130 |
Why?
|
| Cisplatin | 1 | 2015 | 47 | 0.130 |
Why?
|
| Time Factors | 1 | 2019 | 1365 | 0.120 |
Why?
|
| Thymus Gland | 1 | 2015 | 11 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 326 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 126 | 0.120 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 8 | 0.120 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 9 | 0.120 |
Why?
|
| Comorbidity | 1 | 2016 | 466 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 176 | 0.110 |
Why?
|
| Thoracic Cavity | 1 | 2014 | 1 | 0.110 |
Why?
|
| Thoracic Neoplasms | 1 | 2014 | 8 | 0.110 |
Why?
|
| Chicago | 1 | 2016 | 844 | 0.110 |
Why?
|
| Mediastinum | 1 | 2013 | 7 | 0.110 |
Why?
|
| Hernia, Hiatal | 1 | 2013 | 9 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2011 | 50 | 0.110 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2012 | 3 | 0.100 |
Why?
|
| Histone Acetyltransferases | 2 | 2009 | 3 | 0.100 |
Why?
|
| Dyspnea | 1 | 2012 | 37 | 0.100 |
Why?
|
| Histone Deacetylases | 2 | 2009 | 8 | 0.100 |
Why?
|
| Acetylation | 2 | 2009 | 14 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 49 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 119 | 0.100 |
Why?
|
| Age Factors | 2 | 2016 | 744 | 0.100 |
Why?
|
| Fistula | 1 | 2011 | 2 | 0.100 |
Why?
|
| Gastric Fistula | 1 | 2011 | 4 | 0.100 |
Why?
|
| Anastomotic Leak | 1 | 2011 | 7 | 0.090 |
Why?
|
| Living Donors | 1 | 2011 | 7 | 0.090 |
Why?
|
| Lung Transplantation | 1 | 2011 | 13 | 0.090 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2011 | 20 | 0.090 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 31 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 21 | 0.090 |
Why?
|
| Sutures | 1 | 2011 | 43 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2011 | 63 | 0.090 |
Why?
|
| Endoleak | 1 | 2010 | 1 | 0.090 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2010 | 3 | 0.090 |
Why?
|
| Chordae Tendineae | 1 | 2010 | 1 | 0.090 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2010 | 9 | 0.090 |
Why?
|
| Blood Pressure Determination | 1 | 2010 | 14 | 0.090 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 34 | 0.090 |
Why?
|
| Surgical Tape | 1 | 2010 | 3 | 0.090 |
Why?
|
| Endovascular Procedures | 1 | 2010 | 31 | 0.090 |
Why?
|
| Conscious Sedation | 1 | 2010 | 6 | 0.090 |
Why?
|
| Glasgow Coma Scale | 1 | 2010 | 8 | 0.090 |
Why?
|
| APACHE | 1 | 2010 | 29 | 0.090 |
Why?
|
| Equipment Failure | 1 | 2010 | 37 | 0.090 |
Why?
|
| Gastric Bypass | 1 | 2011 | 67 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2010 | 86 | 0.080 |
Why?
|
| Activins | 1 | 2009 | 1 | 0.080 |
Why?
|
| Follistatin | 1 | 2009 | 1 | 0.080 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2009 | 3 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 85 | 0.080 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 7 | 0.080 |
Why?
|
| Iliac Artery | 1 | 2009 | 5 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2010 | 194 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 117 | 0.080 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2009 | 21 | 0.080 |
Why?
|
| Aorta | 1 | 2009 | 13 | 0.080 |
Why?
|
| Multiple Organ Failure | 1 | 2009 | 21 | 0.080 |
Why?
|
| Histones | 1 | 2009 | 24 | 0.080 |
Why?
|
| Transfection | 1 | 2009 | 104 | 0.080 |
Why?
|
| Cattle | 1 | 2009 | 117 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 73 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2009 | 133 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 8 | 0.080 |
Why?
|
| Safety | 1 | 2008 | 39 | 0.080 |
Why?
|
| Debridement | 1 | 2009 | 94 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2008 | 47 | 0.080 |
Why?
|
| Acute Disease | 1 | 2009 | 189 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 124 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 114 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2008 | 79 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2009 | 86 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2009 | 151 | 0.080 |
Why?
|
| Recurrence | 1 | 2009 | 306 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2009 | 119 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2008 | 71 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 340 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 1140 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 670 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2023 | 25 | 0.050 |
Why?
|
| Thrombelastography | 1 | 2022 | 5 | 0.050 |
Why?
|
| Blood Coagulation Tests | 1 | 2022 | 11 | 0.050 |
Why?
|
| Hemostasis | 1 | 2022 | 8 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 5 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2022 | 75 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 16 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 264 | 0.050 |
Why?
|
| Animals | 1 | 2009 | 3390 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 457 | 0.050 |
Why?
|
| Equipment Design | 2 | 2011 | 141 | 0.040 |
Why?
|
| Young Adult | 2 | 2017 | 1853 | 0.040 |
Why?
|
| Mediastinoscopy | 1 | 2019 | 5 | 0.040 |
Why?
|
| Hemolysis | 1 | 2018 | 4 | 0.040 |
Why?
|
| North America | 1 | 2018 | 36 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 26 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 49 | 0.040 |
Why?
|
| Pneumonia | 1 | 2019 | 69 | 0.040 |
Why?
|
| Carcinoma, Embryonal | 1 | 2017 | 3 | 0.040 |
Why?
|
| Dilatation | 1 | 2017 | 8 | 0.040 |
Why?
|
| Tonsillar Neoplasms | 1 | 2017 | 3 | 0.040 |
Why?
|
| Leiomyosarcoma | 1 | 2017 | 21 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 40 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 31 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 67 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 66 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 104 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 7 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 19 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 14 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 93 | 0.030 |
Why?
|
| Minnesota | 1 | 2014 | 7 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 298 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 442 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 55 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 253 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 132 | 0.030 |
Why?
|
| Illinois | 1 | 2014 | 228 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2015 | 130 | 0.030 |
Why?
|
| Cytokines | 1 | 2014 | 226 | 0.030 |
Why?
|
| Algorithms | 1 | 2014 | 358 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 685 | 0.020 |
Why?
|
| Hematemesis | 1 | 2011 | 1 | 0.020 |
Why?
|
| Stomach Ulcer | 1 | 2011 | 3 | 0.020 |
Why?
|
| Esophageal Perforation | 1 | 2011 | 7 | 0.020 |
Why?
|
| Proton Pump Inhibitors | 1 | 2011 | 11 | 0.020 |
Why?
|
| Candidiasis | 1 | 2011 | 19 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 16 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2011 | 7 | 0.020 |
Why?
|
| Surgical Stapling | 1 | 2011 | 5 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 26 | 0.020 |
Why?
|
| Graft Survival | 1 | 2011 | 92 | 0.020 |
Why?
|
| Transducers, Pressure | 1 | 2010 | 4 | 0.020 |
Why?
|
| Aortography | 1 | 2010 | 6 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2011 | 104 | 0.020 |
Why?
|
| Rupture | 1 | 2010 | 106 | 0.020 |
Why?
|
| Obesity, Morbid | 1 | 2011 | 97 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2008 | 5 | 0.020 |
Why?
|
| Azacitidine | 1 | 2008 | 7 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 30 | 0.020 |
Why?
|
| Adipokines | 1 | 2008 | 7 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 116 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 125 | 0.020 |
Why?
|
| Reoperation | 1 | 2011 | 874 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 550 | 0.020 |
Why?
|